1.Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
Kyongsong KIM ; Toyohiko ISU ; Rinko KOKUBO ; Naotaka IWAMOTO ; Daijiro MORIMOTO ; Masaaki KAWAUCHI ; Akio MORITA
Asian Spine Journal 2021;15(3):349-356
Retrospective study. This study aims to evaluate the effectiveness of mirogabalin in treatment of peripheral neuropathic pain due to lumbar spine disease. Mirogabalin is a novel selective ligand for the α2δ subunit of voltage-gated Ca channels. Between April and December 2019, we used mirogabalin to treat 60 consecutive patients (mean age, 67.6 years) with leg symptoms due to lumbar disease. The treatment outcome after 8 weeks of mirogabalin therapy was evaluated by comparing the preand post-administration Numerical Rating Scale (NRS) for leg symptoms and sleep disturbance, the NRS and Roland–Morris Disability Questionnaire for low back pain (LBP), and the quality of life (QOL) score (based on EuroQol five-dimension five-level scale). Mirogabalin treatment was stopped at less than eight weeks in eight patients. The remaining 52 patients for evaluation were divided as group 1 (17 patients who presented with leg symptoms that lasted for less than 3 months) and group 2 (35 patients with leg symptoms that lasted longer than 3 months). The leg symptoms and LBP in both groups significantly improved at 4 and 8 weeks of treatment, and sleep disturbance and QOL were improved at 8 weeks as well. Compared to group 2, the pretreatment leg symptoms and QOL were significantly worse in group 1, and their improvement after 8 weeks of mirogabalin treatment was significantly better ( We have validated the effect of mirogabalin on neuropathic pain due to lumbar spine disease, which has effectively addressed the associated leg symptoms, LBP, and sleep disturbance.
2.Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
Kyongsong KIM ; Toyohiko ISU ; Rinko KOKUBO ; Naotaka IWAMOTO ; Daijiro MORIMOTO ; Masaaki KAWAUCHI ; Akio MORITA
Asian Spine Journal 2021;15(3):349-356
Retrospective study. This study aims to evaluate the effectiveness of mirogabalin in treatment of peripheral neuropathic pain due to lumbar spine disease. Mirogabalin is a novel selective ligand for the α2δ subunit of voltage-gated Ca channels. Between April and December 2019, we used mirogabalin to treat 60 consecutive patients (mean age, 67.6 years) with leg symptoms due to lumbar disease. The treatment outcome after 8 weeks of mirogabalin therapy was evaluated by comparing the preand post-administration Numerical Rating Scale (NRS) for leg symptoms and sleep disturbance, the NRS and Roland–Morris Disability Questionnaire for low back pain (LBP), and the quality of life (QOL) score (based on EuroQol five-dimension five-level scale). Mirogabalin treatment was stopped at less than eight weeks in eight patients. The remaining 52 patients for evaluation were divided as group 1 (17 patients who presented with leg symptoms that lasted for less than 3 months) and group 2 (35 patients with leg symptoms that lasted longer than 3 months). The leg symptoms and LBP in both groups significantly improved at 4 and 8 weeks of treatment, and sleep disturbance and QOL were improved at 8 weeks as well. Compared to group 2, the pretreatment leg symptoms and QOL were significantly worse in group 1, and their improvement after 8 weeks of mirogabalin treatment was significantly better ( We have validated the effect of mirogabalin on neuropathic pain due to lumbar spine disease, which has effectively addressed the associated leg symptoms, LBP, and sleep disturbance.
3.External Validation of the ELAPSS Score for Prediction of Unruptured Intracranial Aneurysm Growth Risk
Mayte Sánchez VAN KAMMEN ; Jacoba P GREVING ; Satoshi KURODA ; Daina KASHIWAZAKI ; Akio MORITA ; Yoshiaki SHIOKAWA ; Toshikazu KIMURA ; Christophe COGNARD ; Anne C JANUEL ; Antti LINDGREN ; Timo KOIVISTO ; Juha E JÄÄSKELÄINEN ; Antti RONKAINEN ; Liisa PYYSALO ; Juha ÖHMAN ; Melissa RAHI ; Johanna KUHMONEN ; Jaakko RINNE ; Eva L LEEMANS ; Charles B MAJOIE ; W Peter VANDERTOP ; Dagmar VERBAAN ; Yvo B W E M ROOS ; René VAN DEN BERG ; Hieronymus D BOOGAARTS ; Walid MOUDROUS ; Ido R VAN DEN WIJNGAARD ; Laura ten HOVE ; Mario TEO ; Edward J ST GEORGE ; Katharina A M HACKENBERG ; Amr ABDULAZIM ; Nima ETMINAN ; Gabriël J E RINKEL ; Mervyn D I VERGOUWEN
Journal of Stroke 2019;21(3):340-346
BACKGROUND AND PURPOSE: Prediction of intracranial aneurysm growth risk can assist physicians in planning of follow-up imaging of conservatively managed unruptured intracranial aneurysms. We therefore aimed to externally validate the ELAPSS (Earlier subarachnoid hemorrhage, aneurysm Location, Age, Population, aneurysm Size and Shape) score for prediction of the risk of unruptured intracranial aneurysm growth. METHODS: From 11 international cohorts of patients ≥18 years with ≥1 unruptured intracranial aneurysm and ≥6 months of radiological follow-up, we collected data on the predictors of the ELAPSS score, and calculated 3- and 5-year absolute growth risks according to the score. Model performance was assessed in terms of calibration (predicted versus observed risk) and discrimination (c-statistic). RESULTS: We included 1,072 patients with a total of 1,452 aneurysms. During 4,268 aneurysm-years of follow-up, 199 (14%) aneurysms enlarged. Calibration was comparable to that of the development cohort with the overall observed risks within the range of the expected risks. The c-statistic was 0.69 (95% confidence interval [CI], 0.64 to 0.73) at 3 years, compared to 0.72 (95% CI, 0.68 to 0.76) in the development cohort. At 5 years, the c-statistic was 0.68 (95% CI, 0.64 to 0.72), compared to 0.72 (95% CI, 0.68 to 0.75) in the development cohort. CONCLUSIONS: The ELAPSS score showed accurate calibration for 3- and 5-year risks of aneurysm growth and modest discrimination in our external validation cohort. This indicates that the score is externally valid and could assist patients and physicians in predicting growth of unruptured intracranial aneurysms and plan follow-up imaging accordingly.
Aneurysm
;
Calibration
;
Cohort Studies
;
Discrimination (Psychology)
;
Follow-Up Studies
;
Humans
;
Intracranial Aneurysm
;
Risk Factors
;
Subarachnoid Hemorrhage
4.Usefulness of Kampo Medicine for Avoiding Polypharmacy Among Hospitalized Patients
Shizuko TAKANO ; Michimi NAKAMURA ; Akira MORITA ; Kouichi RYUU ; Yuuko IZUMI ; Chigusa NAGAI ; Akio YAGI ; Hirohumi SHIMADA ; Kouichi NAGAMINE ; Yoshiro HIRASAKI ; Hideki OKAMOTO ; Takao NAMIKI
Kampo Medicine 2018;69(4):328-335
We investigated the number of drugs and pharmaceutical cost among 159 patients prescribed Western medicine and hospitalized from August 2006 to August 2015 in the Department of Oriental (Kampo) Medicine at Chiba University Hospital. The number of drugs used in Western medicine among improved patients significantly decreased from 5.6 ± 3.6 at hospitalization to 5.3 ± 3.5 at discharge, but the number of Kampo medicine drugs was not changed. The total number of drugs including both Western medicine and Kampo medicine significantly decreased from 7.0 ± 3.8 to 6.7 ± 3.6. The number of drugs used in Western medicine among nochanged patients decreased from 5.1 ± 3.4 at hospitalization to 5.0 ± 3.7 at discharge, but the number of Kampo medicine drugs significantly increased from 1.0 ± 0.0 at hospitalization to 1.3 ± 0.5. The total number of drugs including both Western medicine and Kampo medicine increased from 6.1 ± 3.4 to 6.3 ± 3.9. We thus conclude that a combination of Kampo medicine with Western medicine can be useful for reducing the number of drugs related to polypharmacy. To achieve these results, it is essential to use the concept of sho (a way of pattern recognition of a patient's symptoms in Kampo medicine).
Result Analysis
Print
Save
E-mail